Aditxt, Inc. (ADTX) is a publicly traded company in the Healthcare — Biotechnology industry listed on OTC. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions.
Analysis Summary
Trailing-twelve-month margins: gross margin 19.9%, operating margin -1278.2%, net margin -3623.9%.
At the current price of $0.01, ADTX has negative trailing earnings (P/E not meaningful) and an ROE of 9.26%. Market capitalisation stands at $5M.
Balance sheet quality for ADTX: current ratio of 0.3, net cash position of $192071. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.01 |
| Market Cap | $5M |
| Exchange | OTC |
| Country | US |
Valuation Ratios
| Price / Book | -0.00 |
| EV / EBITDA | -0.24 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 926.02% |
| Return on Invested Capital | -406.31% |
| Return on Assets | -373.57% |
| Gross Margin | 19.89% |
| Operating Margin | -127821.37% |
| Net Margin | -362385.72% |
Financial Health
| Debt / Equity | -0.13 |
| Current Ratio | 0.06 |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| ADTX | Aditxt, Inc. | $5M | 9.3% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price Performance
| 1 month | +131.82% |
| 3 months | -49.00% |
| Year-to-date | -100.00% |
| 1 year | -100.00% |
| 3 years | -100.00% |
| 5 years | -100.00% |
52-Week Range
| 52-week High | $26604.72 |
| 52-week Low | $0.00 |
| Avg Volume (90d) | 296.4M |
Related companies: AIMD · ANL · APLM · ATHA · BLRX · CTXR · GOVX
Explore sector: Healthcare · Biotechnology
More sections of ADTX: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks